Abstract
Objectives To examine how pregnancy loss influences the risk of cardiovascular disease later in life.
Design Prospective historical cohort study.
Setting Danish nationwide health registries.
Participants All Danish women with a recorded pregnancy from 1977 to 2017.
Main outcome measures Venous thromboembolism, myocardial infarction, or ischemic stroke.
Results In this two-part study, part one evaluated the 20-year absolute risk of cardiovascular disease from age 40 among 596,699 women with a full registered reproductive history. Adjusting for calendar year, diabetes, autoimmune disease, live births, and education, the absolute risk of an outcome after 0 and ≥4 pregnancy losses, respectably was: venous thromboembolism 3.0% (95% CI 2.8 to 3.2%) and 5.0% (3.4 to 6.8%); myocardial infarction 1.5% (1.4 to 1.6%) and 2.4% (1.4 to 3.6%); ischemic stroke 2.0% (1.9 to 2.1%) and 2.6% (1.5 to 3.6%). Prior stillbirth increased the absolute risk of later venous thromboembolism by 1.1% (0.2 to 2.3%); myocardial infarction by 1.1% (0.3 to 2.0%).
In study part two, we included 966,490 women from first pregnancy in a time-dependent Cox regression model. Adjusted for confounders, each additional pregnancy loss increased the hazard ratio of venous thromboembolism 1.10 (95% CI 1.07 to 1.13); myocardial infarction 1.12 (1.07 to 1.18); and ischemic stroke 1.10 (1.06 to 1.14). Stillbirth was strongly associated with myocardial infarction before age 40, adjusted hazard ratio of 4.60 (2.65 to 8.00).
Conclusion Pregnancy loss was associated with later venous thromboembolism, myocardial infarction, and ischemic stroke. The absolute and relative risk of outcomes increased in a dose-response manner with increasing numbers of prior pregnancy losses. Stillbirth was strongly associated with myocardial infarction before age 40.
Competing Interest Statement
Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; CTP reports grants from Bayer, grants from Novo Nordisk, outside the submitted work; HSN reports personal fees from Ferring Pharmaceuticals, Merck Denmark A/S, and Ibsa Nordic, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work. AMK reports personal fees from Merck, outside the submitted work; Dr. Westergaard reports grants from Novo Nordisk Foundation, during the conduct of the study.
Funding Statement
The current investigation was funded by a grant from The Research Fund of Rigshospitalet, Copenhagen University Hospital grant number E-22515-01, and Ole Kirks Foundation. The funders had no role in the design of the study, in the collection, analysis, and interpretation of data, in the writing of the report; and in the decision for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data was provided from the Danish Health Data Authority under license FSEID-00003879. Permission was obtained from the Regional Data Protection Agency (P-2020-217).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is not publicaly available. Only aggregated data can be exported for research purposes after relevant approval.
